Opinion|Videos|November 26, 2024
Overview of Stool DNA Test for CRC
Author(s)Vivek Kaul, MD
Key Takeaways
- Colorectal cancer screening is vital for early detection, reducing mortality rates, and preventing cancer progression through timely intervention.
- The USPSTF recommends starting colorectal cancer screening at age 45 for individuals at average risk.
Vivek Kaul, MD, discusses the benefits of using a stool DNA test for colorectal cancer screening, emphasizing its sensitivity, guideline recommendations, and its potential to reduce the screening burden for patients, as well as explaining the test's mechanism of action.
Advertisement
- What are the benefits of using a stool DNA test for screening?
- Sensitivity
- Guideline recommendations
- Reduced screening burden for patients, which has the potential to attract the population not currently participating in screening
- Can you explain how the stool DNA test works and its mechanism of action?
Advertisement
Related to this article
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
52-Week Litifilimab Data in Cutaneous Lupus Erythematosus
3
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
4
Tenapanor Linked to Lower IBS-C Care Use, With Kyle Staller, MD, MPH
5